Vaxxinity (VAXX) Competitors $0.0003 +0.00 (+50.00%) (As of 12/20/2024 04:19 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends VAXX vs. CLVR, NAVB, EVLO, SCPS, GNCAQ, GNCA, ARDS, STAB, AMPE, and CMRAShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Clever Leaves (CLVR), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Scopus BioPharma (SCPS), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Clever Leaves Navidea Biopharmaceuticals Evelo Biosciences Scopus BioPharma Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Comera Life Sciences Clever Leaves (NASDAQ:CLVR) and Vaxxinity (NASDAQ:VAXX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends. Does the media favor CLVR or VAXX? In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score. Company Overall Sentiment Clever Leaves Neutral Vaxxinity Neutral Do insiders & institutionals hold more shares of CLVR or VAXX? 6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Comparatively, 64.1% of Vaxxinity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, CLVR or VAXX? Clever Leaves has a beta of 2702.05, indicating that its share price is 270,105% more volatile than the S&P 500. Comparatively, Vaxxinity has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Is CLVR or VAXX more profitable? Company Net Margins Return on Equity Return on Assets Clever LeavesN/A N/A N/A Vaxxinity N/A N/A N/A Which has higher valuation & earnings, CLVR or VAXX? Clever Leaves has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClever Leaves$17.42M0.00-$17.90M-$11.310.00Vaxxinity$70K0.54-$56.93M-$0.450.00 Does the MarketBeat Community believe in CLVR or VAXX? Clever Leaves received 8 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 81.25% of users gave Clever Leaves an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote. CompanyUnderperformOutperformClever LeavesOutperform Votes1381.25% Underperform Votes318.75%VaxxinityOutperform Votes538.46% Underperform Votes861.54% SummaryClever Leaves beats Vaxxinity on 6 of the 10 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38,000.00$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio0.0010.5989.9717.18Price / Sales0.54195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book0.005.094.784.78Net Income-$56.93M$151.83M$120.23M$225.60M7 Day PerformanceN/A-2.13%-1.92%-1.23%1 Month PerformanceN/A-3.10%11.49%3.36%1 Year PerformanceN/A11.54%30.57%16.60% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.00+50.0%N/A-100.0%$38,000.00$70,000.000.0090CLVRClever LeavesN/A$0.03flatN/A-100.0%$48,000.00$17.42M0.00560NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-99.8%$10,000.00$8,126.000.0010Analyst ForecastEVLOEvelo BiosciencesN/A$0.00+25.0%N/A-98.9%$9,000.00N/A0.00120SCPSScopus BioPharmaN/A$0.00-33.3%N/A-99.3%$8,000.00N/A0.009Gap DownGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5,000.00$3.09M0.0030News CoverageSTABStatera BiopharmaN/A$0.00flatN/A-75.0%$5,000.00$1.49M0.0020AMPEAmpio PharmaceuticalsN/A$0.00+420.0%N/A-99.9%$3,000.00N/A0.0020Analyst ForecastCMRAComera Life SciencesN/A$0.00flatN/AN/A$3,000.00$630,000.000.002 Related Companies and Tools Related Companies Clever Leaves Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Scopus BioPharma Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Comera Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VAXX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
